Loading search results

Outcome Measures

Primary Outcomes (1)

Normalization of ALT levels during pathogenetic therapy for MAFLD at 12 months among study participants taking and not taking carnitine-orotate complex(COC) and biphenyl dimethyl dicarboxylate(BDD)
at 12 months

Secondary Outcomes (10)

Normalization of ALT levels during pathogenetic therapy for MAFLD at 6 months among study participants taking and not taking COC and BDD
at 6 months
Fibrosis level during pathogenetic therapy for MAFLD at 6 and 12 months among study participants taking and not taking COC and BDD
at 6 and 12 months
Steatosis level during pathogenetic therapy for MAFLD at 6 and 12 months among study participants taking and not taking COC and BDD
at 6 and 12 months
Assessment of adherence to COC and BDD therapy against the background of pathogenetic therapy for MAFLD in a cohort taking COC and BDD
up to 12 months since enrollment
Assessment of the impact of COC and BDD against the background of pathogenetic therapy for MAFLD on the quality of life of study participants taking and not taking COC and BDD
up to 12 months since enrollment
+5 more secondary outcomes

Study Arms (2)

Study Cohort

Patients taking Carnitine-Orotate Complex and BDD regardless of study participation. The duration of observation for taking COCs and BDD is 6 months, and the duration of follow-up is 6 months.

Control cohort

Patients who do not take Carnitine-Orotate Complex and BDD, regardless of study participation. Duration of patient observation - 12 months.

Eligibility Criteria

Age18 Years - 75 Years

Sexall

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

Persons aged ≥18 to 75 years inclusive with a diagnosis of metabolic-associated fatty liver disease who are undergoing outpatient monitoring at the place of residence.

You may qualify if:

Patients of both sexes aged 18 to 75 years, who are citizens of the Republic of Kazakhstan;

Study Sites (7)

State-owned public enterprise with the right of economic management "Enbekshikazakh Interdistrict Multidisciplinary Hospital"

Esik, Almaty Region, Kazakhstan

RECRUITING

CONTACT+7(7277)57-32-02 enbekshikaz_crb@mail.ru

Tamilya RashidovaSUB INVESTIGATOR

Guldaria ZaurbaevaSUB INVESTIGATOR

LLP "InkarMed"

Aktobe, Kazakhstan

RECRUITING

Evaluation of the Effectiveness of the Use of a Carnitine-Orotate Complex and Biphenyl Dimethyl Dicarboxylate in the Pathogenetic Therapy of Metabolic-associated Fatty Liver Disease: a Prospective Cohort Study

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (10)

Study Arms (2)

Study Cohort

Control cohort

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (7)

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (10)

Study Arms (2)

Study Cohort

Control cohort

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (7)

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations